Pasithea Therapeutics (NASDAQ:KTTA) Trading 8.5% Higher

Pasithea Therapeutics Corp. (NASDAQ:KTTA – Get Rating)’s stock price traded up 8.5% during mid-day trading on Tuesday . The company traded as high as $0.37 and last traded at $0.37. 25,429 shares were traded during mid-day trading, a decline of 64% from the average session volume of 71,179 shares. The stock had previously closed at $0.34.

Analyst Upgrades and Downgrades

Separately, EF Hutton Acquisition Co. I lowered their target price on shares of Pasithea Therapeutics from $2.30 to $2.00 and set a “buy” rating on the stock in a research note on Monday, April 3rd.

Pasithea Therapeutics Stock Up 8.5 %

The firm’s 50-day simple moving average is $0.39 and its 200-day simple moving average is $0.61.

Institutional Trading of Pasithea Therapeutics

An institutional investor recently raised its position in Pasithea Therapeutics stock. Vanguard Group Inc. grew its stake in Pasithea Therapeutics Corp. (NASDAQ:KTTA – Get Rating) by 104.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 159,844 shares of the company’s stock after purchasing an additional 81,705 shares during the period. Vanguard Group Inc. owned about 0.60% of Pasithea Therapeutics worth $201,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 13.95% of the company’s stock.

Pasithea Therapeutics Company Profile

(Get Rating)

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine.